Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer
Tarek M.A. Abdel-Fatah(University of Nottingham), Srinivasan Madhusudan(University of Nottingham)
Cited by 84
Related Papers
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer
|Molecular Oncology|2014|149
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
|The Lancet Oncology|2017|73
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
|European Journal of Cancer|2013|40